News – Page 28 – Alligator Bioscience

2019-06-18

Alligator Bioscience submits clinical trial application for ATOR-1017

Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2019-06-18

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-06-14

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-05-16

Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study w ...

2019-05-15

Regulatory

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will prese ...

2019-05-09

Lund, Sweden, May 9, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutical ...

2019-04-17

Lund, Sweden, April 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bi ...

2019-04-17

Regulatory

First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...

2019-04-11

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bi ...